De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Recruiting

UstekinumabDe-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Code:

NCT07303686

Conditions

Crohn Disease (CD)

Ulcerative Colitis (UC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ustekinumab 90 mg SC q8w

Ustekinumab 90 mg SC q12w

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-12. This information was provided to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre on 2025-12-26.